Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 1 of 67 
 TITLE PAGE  
 
Protocol Title:   
A prospective multi -center study to evaluate clinical equivalence (method comparison) between  
the BD Microtainer® Easy Collect Capi[INVESTIGATOR_695341]™  and BD Microtainer® Easy Collect 
Capi[INVESTIGATOR_695342]:  
 
Version Number: 4.0 
 
Study Device:   Tube SST™    
 EDTA  
 
Study Type:  
Investigational Device Exemption (IDE)   
 
Short Title:    
 
Sponsor Name: [CONTACT_695412]: [ADDRESS_943336]; Franklin Lakes, NJ [ADDRESS_943337]:  
Nathan Loes  
Sr. Clinical Project Manager  
Nathan.Loes @BD.com  
 
Regulatory Agency Identifier Number(s) : Not applicable  
National Principal Investigator s 
 
 
 
 
 
 
  
Becton  Dickinson and Company  
[ADDRESS_943338]   
Franklin Lakes, NJ [ZIP_CODE]  
Vice President , Global Clinical Developm ent 
 
 
 
 
 
 
 
  
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 2 of 67 
 Version History : 
 
Version Number  Date  Type  
1.0 12/20/2021  Original  
2.0 02/22/2022  Amendment  
3.0 06/06/2022  Protocol updated to include interim analysis (Section 
10.6).  Sponsor Contact [CONTACT_695386]/approvers 
were updated.   Adverse Event (Section 9.1.1.) was 
updated to be consistent with changes being made to 
subsequent  protocols  
4.0 09/07/ 2022  Protocol Updated to specify which Instrument Flags 
will be evaluated  (Section 1.1 Protocol Synops is pg 
11; Section 3 Objectives & Endpoints pgs 23 -24). 
Table 3 – Reference numbers for Vitamin D 
(10995719/10995720) & Total Protein (11097604) 
were updated to reflect the correct assay reference 
numbers used in the study.   Previous Reference 
number for Vit amin D (11201772/11201773) was an 
invalid reference and Total Protein (11097524) is for 
urine analysis which  were listed in error in the 
protocol.  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 3 of 67 
 SPONSOR PROTOCOL APPROVAL  
 
Signature [CONTACT_225456].  
Individual or 
function  Name  [CONTACT_695413]   
 
 
 
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943339] sign the  Clinical 
Study Agreement (CSA) and obtain written approval from the appropriate Institutional 
Review Board (IRB)/Ethics Committee (EC).  
2. The Investigator must receive BD -sponsored training prior to site activation. The 
Investigator is responsible for ensur ing that all Sub -Investigators and clinical staff are 
adequately trained prior to performing any data collection or study -related procedures.   
3. The Principal Investigator [INVESTIGATOR_695343], any m odifications as requested by [CONTACT_1201]/EC, the signed CSA, the ethical 
principles of the Declaration of Helsinki, Good Clinical Practice (ICH E6) / ISO [ZIP_CODE]), 
and applicable national/regional regulations and laws.  
4. If applicable, ensure that written informed  consent is obtained from each participant prior 
to the conduct of any study procedure, using the current IRB/EC approved Informed 
Consent Form.  
 
 
I have read and understand the contents of this  study protocol. I agree to follow and abide by [CONTACT_695387]. I agree to conduct the  trial in accordance with 
the study  protocol,  the signed Clinical Study Agreement, and Good Clinical Practice (GCP) as 
well as applicable FDA and ISO regulations (e.g.,  21 CFR Parts  812, 50, 54, 56; ISO 
[ZIP_CODE]:2011E). I agree to participate in  BD-Sponsored training prior to performing any data 
collection or  study -related procedures.  
 
 
Agreed to by (Investigator):   
  
_______________________________________________   
Printed Name – Investigator    
  
_______________________________________________   
Signature – Investigator   
 
_______________________________________________   
 Site Number  
 
_______________________________________________   
Date   
 
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 5 of 67 
 TITLE PAGE  ................................ ................................ ................................ ................................ .. 1 
Abbreviations  ................................ ................................ ................................ ................................ .. 8 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...... 9 
1.1 Synopsis  ................................ ................................ ................................ ...........................  9 
1.2 Schema  ................................ ................................ ................................ ...........................  17 
2 INTRODUCTION  ................................ ................................ ................................ ................  18 
2.1 Rationale ................................ ................................ ................................ .........................  19 
2.2 Risk/Benefit Assessment  ................................ ................................ ................................  19 
2.2.1  Risk Assessment  ................................ ................................ ................................ ..... 19 
2.2.2  Benefit Assessment  ................................ ................................ ................................ . 21 
2.2.3  Overall Benefit: Risk Conclusion  ................................ ................................ ...........  21 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ......................  21 
3.1 Acceptance Criteria  ................................ ................................ ................................ ........  22 
4 STUDY DESIGN ................................ ................................ ................................ ..................  25 
4.1 Overall Design ................................ ................................ ................................ ................  25 
4.2 Scientific Rationale for Study Design  ................................ ................................ ............  26 
4.2.1  Participant Input into Design  ................................ ................................ ..................  26 
4.3 End of Study Definition  ................................ ................................ ................................ . 26 
5 STUDY POPULATION  ................................ ................................ ................................ ....... 26 
5.1 Inclusion Criteria  ................................ ................................ ................................ ............  27 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...........  27 
5.3 Lifestyle Considerations  ................................ ................................ ................................ . 28 
5.4 Screen Failures  ................................ ................................ ................................ ...............  28 
6 STUDY INTERVENTIONS  ................................ ................................ ..............................  28 
6.1 Investigational/Test Device  ................................ ................................ ............................  28 
6.2 Comparator Devices/Standard of Care  ................................ ................................ ...........  29 
6.3 Ancillary Devices/Products  ................................ ................................ ............................  29 
6.4 Device Labeling  ................................ ................................ ................................ .............  30 
6.5 Measures to Minimize Bias  ................................ ................................ ............................  30 
6.5.1  Randomization  ................................ ................................ ................................ ........  30 
6.5.2  Blinding/Masking  ................................ ................................ ................................ ... 30 
7 STUD Y PROCEDURES AND ASSESSMENTS  ................................ ................................  30 
7.1 Screening, Informed Consent, and Enrollment  ................................ ..............................  31 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943340] Device Blood Collection Procedure  ................................ ................................ ....... 32 
7.4 Repeat Collection  ................................ ................................ ................................ ...........  36 
7.5 Participant Compensation  ................................ ................................ ..............................  37 
7.6 Natural and Contrived Sample Storage and Processing  ................................ .................  37 
7.7 Supplemental Measurements, Visual Observations, and Analyte Testing .....................  39 
7.7.1  Part A: SERUM (Natur al and Contrived Samples)  ................................ ................  41 
7.7.2  Part B: EDTA  ................................ ................................ ................................ ..........  43 
7.8 Natural and Contrived Sample Acceptance and Rejection Criteria for Analyte Testing  46 
7.9 Repeat Testing Natural and Contrived Samples  ................................ ............................  46 
7.10  Residual Sample  Usage (Natural Sample Group Only)  ................................ .................  47 
7.11  Safety Evaluations  ................................ ................................ ................................ ..........  48 
8 PARTICIPANT DISCONTINUATION/WITHDRAWAL ................................ ..................  48 
8.1 Discontinuation/Withdrawal  ................................ ................................ ..........................  [ADDRESS_943341] to Follow -Up ................................ ................................ ................................ ..........  49 
9 ADVERSE EVENTS AND DEVICE DEFICIENCIES  ................................ ......................  49 
9.1 Definitions of  Events  ................................ ................................ ................................ ...... 49 
9.1.1  Adverse Events (AEs)  ................................ ................................ .............................  49 
9.1.2  Serious Adverse Events (SAEs) ................................ ................................ ..............  [ADDRESS_943342] (ADE) / Serious Adverse Device Effect (SADE)  ..............  50 
9.1.4  Unanticipated (Serious) Adverse Device Effect (UADE/[LOCATION_003]DE)  ........................  50 
9.2 Severity of Adverse Events  ................................ ................................ ............................  51 
9.3 Relationship of Adverse Event to Device(s)/Procedure  ................................ .................  51 
9.4 Reporting of Events  ................................ ................................ ................................ ........  52 
9.5 Safety Committees  ................................ ................................ ................................ .........  52 
9.6 Device Deficiencies ................................ ................................ ................................ ........  52 
10 STATISTICAL METHODS  ................................ ................................ ................................ . 53 
10.1  Overview of Study Design  ................................ ................................ .............................  53 
10.2  Sample Size Considerations  ................................ ................................ ...........................  53 
10.3  Analysis Population ................................ ................................ ................................ ........  53 
10.4  General Considerations  ................................ ................................ ................................ .. 54 
10.5  Analysis Methods  ................................ ................................ ................................ ...........  55 
10.5.1  Clinical Equivalence Endpoints  ................................ ................................ ..............  55 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943343]  ................................ ................................ ................  59 
13 ADMINISTRATIVE REQUIREMENTS  ................................ ................................ ............  59 
13.1  Investigator and Site Selection  ................................ ................................ .......................  59 
13.2  Training  ................................ ................................ ................................ ..........................  60 
13.3  Required Documents  ................................ ................................ ................................ ...... 60 
13.4  Publication Policy  ................................ ................................ ................................ ..........  60 
13.5  Study Registration  ................................ ................................ ................................ ..........  61 
13.6  Termination of Study  ................................ ................................ ................................ ..... 61 
14 ETHICAL AND REGULATORY CONSIDERATIONS  ................................ ....................  61 
14.1  IRB/EC Approval  ................................ ................................ ................................ ...........  61 
14.2  Informed Consent and Confidentiality (Natural Samples)  ................................ .............  61 
14.2.1  Confidentiality  ................................ ................................ ................................ ........  62 
14.3  Regulatory Status  ................................ ................................ ................................ ...........  62 
14.4  Statement of Compliance  ................................ ................................ ...............................  63 
15 REFERENCES  ................................ ................................ ................................ .....................  64 
16 APPENDICES  ................................ ................................ ................................ ......................  65 
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943344]  
AE Adverse Event  
AMR  Analytical Measurement Range  
BD Becton , Dickinson,  and Company  
CAL  Clinical Acceptance Limits  
CAP  Capi[INVESTIGATOR_695344] -out Visit  
CRF  Case Report/Record Form  
CSA  Clinical Study Agreement  
CV Coefficient of Variation  
DMP  Data Management Plan  
EDC  Electronic Data Capture  
EDTA  Ethylenediaminetetraacetic acid  
FDA  Food and Drug Administration  
FDAAA  FDA Amendments Act of 2007  
GCP  Good Clinical Practice  
HbA1c  Hemoglobin A1c (glycosylated hemoglobin)  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDE Investigational Device Exemption  
IDS-SM Integrated Diagnostic Solutions – Specimen Management  
IFU Instructions for Use  
IP Interpretive Program  
IRB/EC  Institutional or Independent Review Board/Ethics Committee  
ISO International Organization for Standardization  
IUO Investigational Use Only  
MDL  Medical Decision Levels  
NDA  Nondisclosure Agreement  
OSI Occurrence of Special Interest  
PFH Plasma Free Hemoglobin  
PI [INVESTIGATOR_695345]™  Serum Separator Tube  
UADE  Unexpected Adverse Device Effect  
US [LOCATION_002]  
[LOCATION_003]DE  Unexpected Serious Adverse Device Effect  
VP Venipuncture  
WHO  World Health Organization  
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 9 of 67 
 1 PROTOCOL SUMMARY  
 
1.1 Synopsis  
Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the B   
 Tube SST™  and   Capi[INVESTIGATOR_695346] (method comparison)  of 
the  Tube SST™ and  
 Tube EDTA  to the respective 
comparators (listed below) . 
Part A :  Tube SST™ versus 
Comparator product(s):  
• ® SST™  Blood Collection Tube  
SST)  
•  SST™ Blood Collection Tube  
SST)  
•  Tube with Clot Activator 
and Gel Separator  
 
Part B :  Tube EDTA  versus  
Comparator product(s):  
•  
EDTA)  
•  
EDTA)  
• tube with K 2EDTA  
 
Objectives and Endpoints  
 Objectives and endpoints of this study are provided below.  
Objectives  Endpoints  
Clinical  Equivalence  
SERUM  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 10 of 67 
 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the   
 Tube SST™  and   
Tube EDTA  devices  to respective comparators   
To demonstrate clinical 
equivalence of the   
 
 Tube SST™  (Test 
Device  SST) as compared to 
the relevant comparators for 
chemistry analytes listed in 
Table 3. Average difference between Test 
Device  SST and respective 
comparator device.  
• Test Device  SST vs.  
 Serum  (Venous 
Comparator)  
• Test Device  SST vs.  
 SST (Capi[INVESTIGATOR_695347])  
EDTA  
To demonstrate clinical 
equivalence of the   
 
 Tube EDTA  (Test 
Device  EDTA ) as compared 
to the relevant comparators for 
whole blood parameters listed 
in Table 5. Average difference between 
investigational device and respective 
comparator device.  
• Test Device  EDTA vs.  
 EDTA (Capi[INVESTIGATOR_695347])  
• Test Device  EDTA vs. 
 EDTA 
(Venous Comparator)  
 
Visual Observations and Supplemental Measurements: SERUM  
Evaluation of the frequency of 
selected visual observations in 
the  
 Tube SST™ 
(Test Device  SST)  and all 
comparator tube types:  
•  SST 
•  SST  
•  
Serum  Frequency of selected visual 
observations.  
To evaluate sample hemolysis 
as measured by [CONTACT_695388] (PFH) for  
 Mean and distribution of PFH values 
per tube type and frequency of PFH -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 11 of 67 
 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the   
 Tube SST™  and   
Tube EDTA  devices  to respective comparators   
 Tube  and 
comparators using the 
Siemens Atellica platform.  occurrence above 50mg/dL per tube 
type.  
To evaluate serum collection 
volume of the  
 
 (Test 
Device   tube ).  Serum collection volume as 
measured by [CONTACT_695389]  
 
(Test 
Device   tube ) and 
capi[INVESTIGATOR_695348].  Mean time in seconds between 
puncture timestamp and additive/ 
blood mix start timestamp per tube 
type.  
Visual Observations and Supplemental Measurements: EDTA  
Evaluation of the frequency of 
visual observations in the   
 
 (Test 
Device  EDTA tube ) and all 
comparator tube types:  
•  
EDTA  
•  EDTA  
•  EDTA  Frequency of selected visual 
observations.  
Evaluation of the frequency of 
occurrence of instrument flags 
(both asterisk s and IP 
message s of interest ) in the  
 
 Tube EDTA  
(Test Device  EDTA ) and all 
comparator tube types.  
 Frequency of occurrence of 
instrument flags. Confirmation of 
relevant flags by [CONTACT_695390].  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 12 of 67 
 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the   
 Tube SST™  and   
Tube EDTA  devices  to respective comparators   
version 1.[ADDRESS_943345].  
To evaluate peripheral blood 
smears for samples with 
platelet clump instrument IP 
messages.  • Frequency of occurrence of 
platelet clump instrument flags , 
confirmed by [CONTACT_695391].  
• Frequency of instrument platelet 
clump flags with no platelet 
clumps identified on peripheral 
smear.  
To evaluate whole blood  
collection  volume for the   
 
 Tube EDTA  (Test 
Device  EDTA ). Whole blood collection volume as 
measured by [CONTACT_695392].  
To evaluate duration of 
sample collection for the   
 
 Tube EDTA  (Test 
Device  EDTA ) and capi[INVESTIGATOR_695349].  Mean time in seconds between 
puncture timestamp and 
additive/blood mix start timestamp 
per tube type.  
Device Safety Assessment  
To assess the safety of the 
Test Device  SST and EDTA 
systems.  Device/procedure - related adverse 
events (AEs).  
For Informational Purposes  Only :  
SERUM  
Evaluate clinical equivalence 
between comparator tubes for 
the chemistry analytes listed 
in Table 3. Average difference for tube 
comparisons.  
• Test Device  SST tube vs. 
 SST tube 
(Venous Comparator)  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 13 of 67 
 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the   
 Tube SST™  and   
Tube EDTA  devices  to respective comparators   
•  vs. 
 Serum  
•  SST vs. BD 
SST tube  
•  SST tube vs. 
 Serum  
EDTA  
Evaluate clinical equivalence 
between comparator tubes for 
all analytes listed in Table 5. Average difference between the 
following devices  
• Test Device  EDTA tube vs. 
 EDTA  
•  vs.  
 EDTA  
•  EDTA vs.  
 EDTA.  
•  EDTA vs. 
 EDTA  
Design and Overview  This is a prospective, multi -center study designed to evaluate the safety 
and effectiveness of the  Tube 
SST™  and  Tube EDTA 
devices.  
This study will be conducted in two parts; Par t A will evaluate the  
 Tube  device and Part B 
will evaluate the  Tube EDTA 
device.  A minimum of 100 participants , and a maximum of 150 
participants  per part will be enrolled at a minimum of three various 
 site settings representative of the intended use 
environment  
  
Samples will be collected by  
 
 
. Comparator venous and  conventional  capi[INVESTIGATOR_695350] . Samples will be co llected, clotted - Protocol | 

Protocol Number:  CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
Page 14 of 67 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the 
 Tube SST™  and 
Tube EDTA  devices  to respective comparators  
(serum samples  only) and centrifuged within 2 hours of collection 
(serum samples  only) prior to testing , within 4 hours of collection  (see 
Section 7).  
The study population will include apparently healthy participants and 
patient populations ≥18 years of age , covering a range of disease states 
(See Section 5). The goal is to maximize coverage of the assay 
measurable range for each analyte, including above and below medical 
decision levels  and at the extremes of the range, with natural samples  
wher e possible . 
Approximately 10 % contrived samples  will be prepared for each 
analyte to cover the assay measurable range  (AMR).  Preparation of 
these samples will be described under a separate Spi[INVESTIGATOR_695351]. An 
overview of the spi[INVESTIGATOR_695352] B. 
Study Device  , Investigational 
Use Only (IUO)  
The BD Microtainer ® Easy Collect Capi[INVESTIGATOR_695341]™  is a part of 
the prototype capi[INVESTIGATOR_695353]  a capi[INVESTIGATOR_695354].   Additional details are 
provided in Section 6.1 
 Tube EDTA , Investigational 
Use Only (IUO)  
 Tube  EDTA  is 
blood container with K 2EDTA anticoagulant. 
Participants  •Participants will fall under two groups : Natural Sample Group
(uncontrived)  and Contrived Sample Group. The Contrived Sample
Group of participants will be enrolled
. The collection of blood, and 
preparation of the contrived samples from the blood collected from 
these subjects is outlined in the overview presented in Appendix B. 
Detailed instructions will be provided in a separate  Spi[INVESTIGATOR_695355]. -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 15 of 67 
 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the   
 Tube SST™  and   
Tube EDTA  devices  to respective comparators   
• Participants  ≥18 years of age recruited  
 in-person, via phone, or 
via electronic communications using IRB -approved recruitment 
materials.  In order to cover the assay  measurable range (AMR) 
additional in - and out -patient hospi[INVESTIGATOR_695356].  
• Part A: Patients with hepatic, renal, endocrine, cardiovascular 
disorders and/or cancer.  
• Part B: Patients wi th hematological disorders, cancers, diabetes 
and/or allergies.  
Intervention(s)/Procedure(s)  After completing the informed consent process and enrolling into the 
study, blood will be collected from participants  using a predetermined 
randomization schedule  which will include randomized collection  type 
(venous or capi[INVESTIGATOR_1396]) and tube draw order .  
Participants in study Part A will have   collections 
performed using the Test Device  SST, and two ( 2) conventional 
 collections performed using the currently marketed   
  device . A standard venipuncture will also be 
performed to collect samples in to   
 comparator tube s. An approximate blood volume of 
[ADDRESS_943346] samples into the  
EDTA and    EDTA  comparator tubes.  An 
approximate blood volume of 5 mL will be collected from participants 
in Part B. 
Samples will be mixed and processed per their respective IFUs.  
Samples will be transported to  laboratory for analysis within 
4 hours of collection end time for serum tubes and within 4 hours of 
collection end time for EDTA tubes.  The collection  end time 
(additive/blood mix start timestamp ) for each conventional and Test 
Device  capi[INVESTIGATOR_695357] a participant will be noted on the 
CRF.  For venous collections, the collection  end time (additive/blood 
mix start timestamp ) will be the time  of the last tube collected  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 16 of 67 
 Protocol Title  A prospective multi -center study to evaluate clinical equivalence 
(method comparison) between the   
 Tube SST™  and   
Tube EDTA  devices  to respective comparators   
. Analysis time is defined as the time at which the 
sample is aspi[INVESTIGATOR_695358].  
Investigational Sites  This study will be conducted  at a minimum of 3 sites in the US.   
 
 
Data Monitoring Committee  Not applicable  
Regulatory Status  IDE Exempt  
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 17 of 67 
 1.2 Schema  
 
Natural Sample  Group  
Part A  
Part B  -- Protocol 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 18 of 67 
 Contrived Sample  Group  
A Sch ema which provides an  overview of the spi[INVESTIGATOR_695359] i s presented in  Appendix B . 
Details of the collection of blood and preparation of the contrived samples will be provided 
in a separate Spi[INVESTIGATOR_695355].  
 
2 INTRODUCTION  
 
BD Integrated Diagnostic Solutions – Specimen Management (IDS -SM) manufactures a 
range of tubes  
for clinical testing.   
 
Currently, the method for collection of a large volume of capi[INVESTIGATOR_17276] (up to 600 µL) 
involves optional warming of the hand or finger prior to procedure, lancing of the fingertip, 
squeezing the fingertip by [CONTACT_35681], and drippi[INVESTIGATOR_695360] -sterile tube. The 
capi[INVESTIGATOR_695361]. Common sample quality issues for capi[INVESTIGATOR_695362] d dilution of sample with interstitial fluid , potentially causing 
bias in test results. Open collection also carries a risk of blood exposure for healthcare 
workers and potential risk of infection at the finger puncture site.   
 
 
 
 
 
  
  
  
  
  
  
  
 
  
  
 
   
 
 
 
 
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 19 of 67 
  
 
   
 
 
 
  
 
 
 
 
 
 
 
 
2.1 Rationale  
 
 
          
  
 
 
2.2 Risk/Benefit Assessment  
 
This study provides no direct health benefit to the participants but is associated with minimal 
risk.  The risks to participants are in line with standard blood collection procedures.  
 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of  capi[INVESTIGATOR_695363].  
 
 
 
 
 
2.2.1 Risk Assessment  
 
Potential Risk of Clinical 
Significance  Summary of 
Data/Rationale for 
Risk  Mitigation Strategy  
Study Intervention:  
 
• Since the  blood 
collection  tubes may contain Package insert  • Venipuncture will be performed 
using commercially available sterile 
evacuated blood collection tubes -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 20 of 67 
 Potential Risk of Clinical 
Significance  Summary of 
Data/Rationale for 
Risk  Mitigation Strategy  
chemical additives, backflow 
may cause adverse reactions . 
 
• There is  a risk of blood exposure 
for study staff should a study 
tube leak or break.  following standard venipuncture 
procedure and best practices fo r 
venipuncture. During the 
venipuncture procedure the 
participant’s arm will be placed in a 
downward position; tubes will be 
held with the stopper uppermost; The 
tourniquet should be released as soon 
as blood starts to flow; and care is 
taken to make sure the additives do 
not touch the stopper or end of the 
needle during venipuncture  
• Study staff will use 
Universal/Standard Precautions 
during all procedures where exposure 
to blood/blood components may be 
possible.  
Study Procedures: Blood Specimen Collection  
Blood collection by [CONTACT_695393]:  
• Slight/moderate discomfort at 
the collection site  
• Bruising/hematoma  
• Scarring  
• Infection  
• Syncope  
• Nausea/vomiting   Common medical 
knowledge; package 
insert  • Venipuncture will be performed by 
[CONTACT_695394] . 
• Venipuncture will be performed at a 
location with sufficient  medical  
facilities  by [CONTACT_695395].  
Capi[INVESTIGATOR_695364]-sterile collection tube and 
finger device  (if applicable ) may 
have a risk of non -sterile surfaces 
touching skin at the puncture site 
leading to a potential risk of 
infection  
 
 Instruction for use; 
package insert  • Disinfection of the finger puncture 
site and the interior surface of the 
finger device , that is in contact [CONTACT_695396], with disposable alcohol 
wipe will be performed prior to 
capi[INVESTIGATOR_695365]  
•  
 
 
 will be 
instructed to follow universal 
precautions/ risk mitigation -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 21 of 67 
 Potential Risk of Clinical 
Significance  Summary of 
Data/Rationale for 
Risk  Mitigation Strategy  
procedu res to minimize blo od 
exposure.  
• New devices will be used for each 
individual  collection.  
• The  device  will be disinfected 
prior to use  
• The skin at the puncture site will be 
disinfected prior to collection.  
• The  tool is  
 and will be discarded after each 
participant  use. 
Other  
Discomfort during capi[INVESTIGATOR_695366]  • Devices will be removed 
immediately upon participant  
request due to pain or discomfort.  
• Skin irritation or allergy from 
devices will be mitigated by 
[CONTACT_695397].  
 
2.2.[ADDRESS_943347] benefits to the participant  for participation in this study.  The 
findings may reveal information that will allow for the development of a new 
capi[INVESTIGATOR_695367], and thus may improve medical care 
for persons that undergo blood collection procedures.   
 
2.2.3 Overall Benefit: Risk Conclusion  
 
While there are no direct benefits to participants in this study, it is possible that the 
informatio n gathered could benefit patients in the future.  There are no known or 
anticipated risks associated with the use of any  study device  other than those 
associated with general blood collection procedures.  Potential risks for participants 
are well known, ha ve been minimized as reasonably feasible. The risk is low with 
a little chance of prolonged sequelae.  
 
3 OBJECTIVES AND ENDPOINTS  
 -- Protocol |

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 22 of 67 
 3.1 Acceptance Criteria  
For each comparison, clinical equivalence will be demonstrated for an analyte if the mean 
biases with 95% limits are within the Clinical Acceptance Limits (CAL).  
• If the mean bias is within the CAL but the 95% limit exceeds the CAL, it will be 
considered clinically non -equivalent, requiring further interpretation and assessment 
to determine whether the differen ce is clinically acceptable. This assessment will be 
made based on impact on patient diagnosis and treatment.   
• If the mean bias exceeds the CAL at any medically relevant points, it will be 
considered clinically non -equivalent and will be considered clinic ally unacceptable, 
unless a rationale can be provided.  
 
Objectives  Endpoints  
Clinical Equivalence  
SERUM  
To demonstrate clinical equivalence of the 
 
 (Test Device  SST) as compared to the 
relevant comparators  for chemistry analytes 
listed in  Table 3. Average difference between investigational device and 
respective comparator device.  
• Test Device  SST vs.  
(Venous Comparator)  
• Test Device  SST vs.  
(Capi[INVESTIGATOR_695368])  
EDTA   
To demonstrate clinical equivalence of the 
 
 (Test Device  EDTA ) as compared to 
the relevant comparators for whole blood 
parameters  listed in Table 5. Average difference between investigational device and 
respective comparator device.  
• Test Device  EDTA vs.  EDTA 
(Capi[INVESTIGATOR_695368])  
• Test Device  EDTA vs.  
EDTA (Venous Comparator)  
Visual Observations and Supplemental Measurements : SERUM  
Evaluation of the frequency of selected visual 
observations in the    
 (Test Device  
SST) and all comparator t ube types : 
•  
•   Frequency of selected visual observations  (Table 4). -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 23 of 67 
 • Greiner Vacuette Serum  
To evaluate sample hemolysis as measured 
by [CONTACT_695398] (PFH) on 
Siemens Atellica platform for  
  
 and all comparator  tube type s:  
•  
   
  Mean and distribution of PFH values per tube type and 
frequency of PFH occurrence above  per tube 
type.  
To evaluate serum collection volume of the 
Test Device  SST tube   Serum collection v olume as measured by [CONTACT_695399]  
 
(Test Device  SST tube) tube and 
capi[INVESTIGATOR_695369]/  blood mix start timestamp per tube type.  
Visual Observations and Supplemental Measurements : EDTA  
Evaluation of the frequency of visual 
observations in the    
 (Test Device  
EDTA  tube) and all comparator tube types : 
  
  
  Frequency of selected visual observations  (Table 4). 
Evaluation of the frequency of occurrence of 
instrument flag s (both asterisk s and IP 
message s of interest ) in the  
 (Test 
Device  EDTA ) and all comparator tube types : 
•  
  
  
 
 
 Frequency of occurrence of instrument flags. 
Confirmation of relevant flags by [CONTACT_695390].  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 24 of 67 
 To evaluate peripheral blood smears for 
samples with platelet clump instrument IP 
messages . • Frequency of occurrence of platelet clump 
instrument flags, confirmed by [CONTACT_695391].  
• Frequency of instrument platelet clump flags with 
no platelet clumps identified on peripheral smear.  
To evaluate  whole blood collection  volume 
for the   
 (Test Device  EDTA ) Whole b lood collection volume as measured by [CONTACT_695400].  
To evaluate  duration of  sample collection  for 
the  
 EDTA and 
capi[INVESTIGATOR_695348] -  Mean time in seconds between puncture timestamp and 
additive/blood mix start timestamp per tube type.  
 Device Safety Assessment  
To assess the safety of the  Test Device  SST 
and EDTA systems.  Device/procedure - related adverse events (AEs).  
For Informational Purposes  Only :  
SERUM  
Evaluate clinical equivalence between 
comparator tubes  for the  chemistry analytes 
listed in Table  3. Average difference for tube comparisons.  
• Test Device  SST tube vs.  
 (Venous Comparator)  
•  SST vs.  
Serum  
•  SST vs.  SST 
tube  
•  SST™ tube  vs.  
 Serum  
EDTA  
Evaluate clinical equivalence between 
comparator tubes  for all analytes listed in 
Table 5. 
 Average difference between the following devices  
• Test Device  EDTA tube vs.  
  
•  EDTA  vs.  EDTA  
•  EDTA  vs.  EDTA  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 25 of 67 
 •  EDTA  vs.  
EDTA  
 
4 STUDY DESIGN  
 
4.1 Overall Design  
 
This is a prospective, multi -center randomized collection study designed to evaluate the 
safety and effectiveness of the  Blood Collection 
System  using the  (SST™  and EDTA)  and 
to provide the necessary data to demonstrate substantial equivalence of these  Test Device  
tubes to the ir respective comparators.  
This study will be conducted in two parts; Part A will evaluate the Test Device  SST™  tubes 
and Part B will evaluate the Test Device  EDTA tubes .  A minimum of [ADDRESS_943348] prior blood collection 
experience.  Person s who perform  
 
. Prior to participation in the study , all users will receive train ing on 
use of study products.   tubes will be collected 
. Persons who perform collection of the c omparator  
 
Samples will be collected, clotted ( serum samples  only), centrifuged  (serum samples only), 
and transported  prior to analyte testing at . Note: Serum samples must 
be centrifuged within 2 hours of collection time  (see Section 7).  
The study population will include apparently healthy participants and patient populations 
covering a range of disease states (See Section 5). The goal is to maximize coverage of the 
assay measurable range for each analyte, including above and below medical decision levels 
and at the extremes of the range, with natural samples , whe re possible . An overview  of the 
reference range, critical values, and assay measurable range for each parameter is provided 
in Appendix A.   
 
To ensure measurements are obtained  to cover the assay measurable range (AMR), 
approximately 10% contrived samples will be prepared for each analyte .  Preparation of 
these samples will be described under a separate Spi[INVESTIGATOR_695355]. A separate group of 
approximately  20 participants will be  enrolled  
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943349] Device s,  
 
 
 
The analytes selected to be tested in this study represent  the intended use of the device s. 
 
The patient population was selected in order to cover the assay measurable range (AMR) 
using natural (uncontrived) samples to reflect real -world use.  Measurements of certain 
analytes at the extreme ends of the AMR may not be sustainable to life  or it may just not 
be possible to recruit the participants  to span the full range . Therefore, i n order to cover 
this range,  approximately 10% of the paired samples used in each analysis  may be 
contrived . 
 
4.2.[ADDRESS_943350] completed the study after he/she has completed blood 
collection  and is discharged from the collection location , even if not all the study tubes are 
collected . 
 
The end of the study is defined as the date of the analysis of the samples collected from the 
last participant in the stud y.  
 
5 STUDY POPULATION  
Natural Sample Group  
Participants will be recruited  
 in-person, via phone, or via 
electronic communications , such as social media, using IRB -approved recruitment materials . 
In order to cover  the assay  measurable range (AMR) additional in - and out - patient hospi[INVESTIGATOR_695370].  
• Part A: Patie nts with hepatic, renal, endocrine, cardiovascular disorders and/or cancer.  
• Part B: Patients with hematological disorders,  cancers,  diabetes  and/or allergies.  -- Protocol |

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943351] 30% of either gender   
. The patient disease state and gender will be documented  on a CRF . 
 
Contrived Sample Group  
Participants enrolled  for the preparation of contrived samples  
 
  
 
5.[ADDRESS_943352] meet all of the following 
criteria:   
1. Participants ≥18 years of age . 
2. Not currently pregnant (self -reported)  
3. Adequate access to  four fingers   and inner 
elbows for blood collection procedures  
4. Willing and able to comply with all study procedures and evaluations  
5. Ability to read, write, and understand English language  
6. Provision of signed and dated informed consent form  
 
Contrived Sample  Group  
Participants enrolled  for the preparation of contrived samples  must meet the criteria laid  out 
within the . Participants who have been enrolled within  have 
already been screened according to the inclusion criteria  for that program . 
 
5.2 Exclusion Criteria  
 
Natural Sample  Group  
Participants are excluded from the study if any of the following criteria apply:  
 
1. Evidence of skin issues such as infections, ulcerations, blisters, peripheral vascular 
disease , inflammation, extensive scarring or calluses, or healed burns at the 
 site.  
2. Subject  to post -study exclusion period for this or other related studies : 
a. A study participant may enroll once in study part A and once in study part 
B of this clinical study. They may not enroll more than once in a single 
study part.  
b. If a study participant has previously enrolled in one study part and  would 
like to enroll in the second study part, they must wait  from the time 
of the first study part collection  procedures  to enroll  in the second study part 
collection procedures . -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943353] meet the criteria  
 
 
 
5.3 Lifestyle Considerations  
 
There are no  required lifestyle cons iderations or restrictions . 
 
5.4 Screen Failures  
 
Screen failures are defined as participants who do not meet all eligibility criteria.   
Individuals who do not meet the criteria for participation in this study (screen failure) may 
not be rescreened.  
 
6 STUDY INTERVENTIONS  
 
6.1 Investigational/ Test Device  
 
 
 
 
 
 
   
 
 
  
 
   
 
  
 
  
 
   
  
  
  
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 29 of 67 
   
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
6.2 Comparator Device s/Standard of Care  
 
Part A  
• [T03 -T04]  SST™  Tube  SST), 400 -600 µl, 
, or equivalent.  
• [T05]  SST™ Blood  Collection Tube (  SST),  
, , or equivalent.  
• [T06]  Blood Collection Tube with Clot Activator and Gel 
Separator   or equivalent.  
 
Part B  
• [T08]  
EDTA),  or equivalent.  
• [T09]  EDTA), 
 or equivalent.  
• [T10]  
EDTA) ,  
 
6.3 Ancillary Devices/Products  
 
•  
  
  
  
 
  
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 30 of 67 
 6.4 Device Labeling  
 
Investigational devices (or the immediate packaging) shall be labeled in accordance with 
regulatory requirements, including the following statement : "For Investigational Use 
Only ”. The performance characteristics of this product have not been established."  
 
The devices used during current  venipuncture  collection practice s and capi[INVESTIGATOR_695371] s are all commercially available and will be labeled as provided by [CONTACT_13989].  
 
For contrived samples  blood will be collected from participants  
 
  
 
6.5 Measures to Minimize Bias  
 
6.5.1 Randomization  
 
All randomization schedules are to be provided by [CONTACT_225447] . 
Natural Sample  Group  
Collection method (venous vs. capi[INVESTIGATOR_1396]), tube collection order (within collection method) , 
 location   will be randomized according 
to a draw schedule.   
 
 
Contrived Sample  Group  
For the contrived samples, indirect draw order will be randomized according to a draw 
schedule.  Tube testing order on instrument will be randomized according to a test schedule . 
 
6.5.2 Blinding/Masking  
 
Not applicable, this is an open -label study.  
 
7 STUDY  PROCEDURES AND ASSESSMENTS  
 
• Study procedures , assessm ents for natural samples  and their timing are illustrated in 
the respective schemas provided in Section 1.2. Protocol waivers or exemptions are 
not al lowed.  
• Adherence to the study design requirements is essential and required for study 
conduct.  
• Procedures conducted as part of the participant’s routine clinical management (e.g., 
blood count) and obtained before signing of the ICF may be utilized for scre ening or 
baseline purposes provided the procedures met the protocol -specified criteria.  
• The I nstructions for Use (IFU)  is a reference document  for the investigational Test 
Device  product ; this study protocol will supersede the Test Device  IFU. -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943354] procedures, information to be collected, number and 
type of blood collection procedures, potential risks and benefits, and other pertinent 
information.   
 
 
 
 
 
 
  
 
Part A  
Natural Sample Group:  
Contrived Sample Group:  
 
Part B  
Natural Sample Group:  
Contrived Sample Group:  
 
 
 
  
 
7.2  Blood Collection  Procedure  
 
Natural Sample  Group  
Study Part A:   
For each participant,  one venipuncture using a  to 
collect blood into a  tube. The collection 
will be performed per the study site’s standard operating procedure for venipuncture.  In 
addition,  collections using 
. A  
 
 the Test Device   system . The collection end time 
 for each conventional and Test Device  capi[INVESTIGATOR_695372] a participant will be noted on the CRF. For venous collections, the collection 
end time will be the time of the last tube collected from a venipuncture draw. Duration of 
collection  for all capi[INVESTIGATOR_695365] (conventional and Test Device ) will also be captured -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 32 of 67 
 on CRFs as described in section 7.7 of this protocol, Supplemental Measurements, Visual 
Observations, and Analyte Testing . Study Samples will be mixed and proc essed per their 
respective IFUs.  
 
Study P art B:  For each participant,  one venipuncture  
 to collect blood into a  
tube. The collection will be performed per the study site’s standard operating procedure for 
venipuncture. In addition,  one (1) conventional capi[INVESTIGATOR_695373].  
 collection  using the  
 Test Device  EDTA system . The collection end 
time  for each conven tional and Test Device   
tube collected from a participant will be noted on the CRF. For venous collections, the 
collection end time will be the time of the last tube collected from a venipuncture draw. 
Duration of collection for all capi[INVESTIGATOR_695374] (conventional and Test Device ) will also 
be captured on CRFs as described in the supplemental measurements section, section 7.[ADDRESS_943355] Device  Blood Collection Procedure  
 
Natural Sample  Group  
 
 
 
 
  
 
 
 
 
 
  
 
 
  
 
  
 
 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 33 of 67 
   
  
  
 
 
  
 
  
  
 
  
 
 
  
 
 
 
  
 
  
  
 
  
  
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 34 of 67 
   
  
  
 
 
 
 
  
 
  
 
 
 
 
   
   
  
  
  
  
   
  
 
 
 
 
 
   
  
 
  
  
 
  
  
 
  
  
 
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 35 of 67 
   
  
  
  
  
 
  
 
 
Step 9: Apply Gauze  
• Apply the sterile gauze or pad to  the puncture site.  Direct the patient to hold and 
apply pressure if they are able to assist.  
 
 
  
 
 
 
  
 
 
 
 
 
 
  
 
 
The collection end time for each conventional and Test Device   tube collected from 
a participant will be noted on the CRF. For venous collections, the collection end time will 
be the time of the last tube collected from a venipuncture draw  
 
Contrived Sample  Group  
The procedures for the  collection of blo od for the preparation of the  contrived samples are 
outlined in the overview of the spi[INVESTIGATOR_695375] B.  
 
Once the contrived samples are indirectly transferred into the study tubes , they will be 
processed in the same manner  as the natural samples.  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 36 of 67 
 7.4 Repeat Collection  
 
In cases of insufficient sample volume or loss of sample during collection, r epeat collection 
may be  needed.   Repeat collection will vary based on blood collection method.  Participants 
should be asked for their permission before attempting a r epeat collection.  
 
Natural Sample  Group  
Part A:  SERUM  
Capi[INVESTIGATOR_695376]  – A total of four capi[INVESTIGATOR_695377] , the 
subject will be included in the study and the missing tubes will be noted.  
 
Venipuncture  – 1 additional  venipuncture will be allowed , for a total of 2 venipunctures 
for Part A of this study . 
 
Part B:  EDTA  
Capi[INVESTIGATOR_695376]  – A total of two capi[INVESTIGATOR_695378]: [ADDRESS_943356] ures for 
Part B of this study.  
 
Contrived Sample  Group  
Repeat collections on participants  enroll ed for the preparation of contrived samples  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 37 of 67 
  
7.5 Participant Compensation  
 
Participants will be compensat ed for their time and participation after the study procedures 
are complete . 
 
7.6 Natural and Contrived  Sample S torage and Processing  
 
 
 
 
  
  
 
  
  
 
 
  
  
 
  
 
  
 
 
 
  
  
  
  
   
 
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 38 of 67 
  
Part A: SERUM  
 
After tube inversions, all  Serum  tubes need to stand for their minimum clot times and then 
centrifuged as indicated in Table 1.  
 
            
 
. All tubes from the same participant  
 will be centrifuged within the same timeframe.  Remove 
samples from centrifuge as soon as centrifugation is completed.  
. 
 
For Natural samples, a ll tubes from the same participant will be processed and tested at the 
same timef rame  using the same lot of reagents.  For contrived samples , all tubes from the 
same  pool set  will be processed and tested at the same timeframe  using the same lot of 
reagents.  
 
 
 
 
 
 
 
 
 
 
Part B: EDTA  
 
Complete tube inversions as indicated  in Table [ADDRESS_943357] Device  container into adapter for automated processing 
on the instrument.  
 
-- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 39 of 67 
  
 
 
 
 
  
 
Table 1:  Tube Processing  
Tube 
Number  
Tube type  Inversions * Minimum Clot 
Time  Centrifugation †  
Time  G-force (g)  
T01, T02   
     
T03, T04   
 5 45 min 90 sec  6500 
T05   
 5 30 min  10 min  1300  
T06  
 5 30 min  10 min  1800  
T07  
  N/A N/A N/A 
T08  
 
 8 N/A N/A N/A 
T09  
 8-10 N/A N/A N/A 
T10  
 
 8-10 N/A N/A N/A 
†All serum tubes will be centrifuged within 2 hours of their respective collection end time . All tubes from the same 
participant (Natural Sample Group) or from the same contrived sample pool will be centrifuged within the same 
timeframe  
*Mix blood with additives in the tubes immediately after collection using the indicated num ber of tube inversions  
 
 
7.7 Supplemental Measurements , Visual Observations , and Analyte Testing  
 
• Duration of collection  (applicable to only Natural Samples) : Defined as time in 
seconds between puncture timestamp and additive/blood mix start timestamp per -- Protocol |

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 40 of 67 
 tube type. This parameter will only be collected for tubes T01 -T04, Capi[INVESTIGATOR_695379].  
• Volume of Serum  (applicable to only Natural Samples) :  
 
 
• Plasma, Free Hemoglobin  (applicable to Natural and Contrived Samples) : As 
measured on Siemens Atellica . 
 
The following visual  observation s will be assessed during part A for Natural Samples . For 
Contrived Samples all visual observations in Table 2 also apply with the exception of the visual 
observation for collection failure.   
 
Table 2:Visual Observations for Part A  
Visual 
Observation  Rating  Description  Ideal 
Rating  Note  
Complete Fill  1, 2, (3)   
 
 
 
 
 
 
 
 
 
 
 2 Performed 
after 
collection, 
right before 
mix start 
timestamp  
Collection Failure  0, 1, 2, 3, 4   
 
 
 
 
 
 
 
 
 0 -- Protocol | 
Downloaded on [ADDRESS_943358] 2023
System Version Number 1.0

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 41 of 67 
  
Fibrin mass 
(distinct from fibrin 
strands)  0, 1, 2, 3   
 
 
 
 
 
 
 0 Performed as 
soon as 
possible after 
centrifugation  
and prior to 
testing   
Fibrin strands 
(distinct from fibrin 
masses)  Y/N  
 
 N 
Gel Barrier 
formation  0, I, C    
 
 C 
Red blood cell s on 
barrier  0, 1, 2, 3   
 
 
 0 
Hemolysis  0, 1, 2, 3   
 
 
 0 
*Complete fill will be determined by [CONTACT_695401] ( reference  tubes ). 
 
 
 
7.7.1 Part A : SERUM  (Natural and Contrived Samples)  
 
Serum samples from the Test Device   and comparator tubes will be tested (‘analysis 
time’) on the Siemens Atellica platform after centrifugation as noted in Table 3 and within 
4 hours from  the collection end time. For the contrived samples the full panel of analytes 
may no t be ru n on each contrived sample set. T he specific analytes  to be tested for each 
contrived sample set will be detailed in the Spi[INVESTIGATOR_695355]. Analysis time is defined as the -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943359] tubes should be  to enable serum sampling from 
the primary tube.  tubes may be aliquoted into sample c ups prior to 
analysis.  
 
Table 3: Analytes to be Measured in Part A  Natural and Contrived Samples  
Analytes  Abbreviation    
Immunoassays  
Thyroid -Stimulating 
Hormone  TSH   
  
Vitamin D  Vit D   
  
Enzyme  
Alkaline Phosphatase  ALP    
Alanine Aminotransferase  ALT    
Aspartate 
Aminotransferase  AST    
Lipid  
High -Density Lipoprotein  HDL    
Low-Density Lipoprotein  LDL    
Total Cholesterol  CHOL    
Triglycerides  TRIG    
Metabolic  
Albumin  ALB    
Total Bilirubin  TBIL    
Blood Urea Nitrogen  BUN    
Calcium  Ca  
Carbon Dioxide  CO2    
Chloride  Cl   -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 43 of 67 
 Creatinine  CRE    
Glucose  GLU    
Potassium  K   
Sodium  Na   
Total Protein  TP   
 
By [CONTACT_15094] , TSH will be  measured in capi[INVESTIGATOR_156627] T01  and T03   
 The remaining chemistry analytes will be tested from T02  (Test Device  SST)  
and T04  .  If necessary , leftover serum from either tube  of the same tube 
type, from the same participant  can be used for repeat analysis, only for the analytes listed above . 
 
7.7.2 Part B : EDTA  
Supplemental Measurements:  
• Duration of collection  (applicable to only Natural  Sample s):  
 
. This parameter will only be collected for , T07 and 
T08. 
• Volume of Whole Blood  (applicable  to only Natural Sample s):  
 
 
 
• Smear Reviews:  (applicable to Natural and Contrived Sample s) Peripheral smears 
will be reviewed in response to  applicable  instrument flags.  Details on smear 
reviews provided below.  
 
The following visual  observations  will be assessed during part B for Natural Samples . For 
Contrived Samples only the  visual observation of complete fill will be assessed.  
Table 4:  Visual Observations for Part B  
Visual 
Observation  Rating  Description  Ideal 
Rating  Note  
Complete Fill  1, 2, (3)  
 
 
 2 
 
 Performed after 
collection, right 
before mix start 
timestamp  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 44 of 67 
  
 
 
 
 
 
 
 
Collection 
Failure  0, 1, 2, 3, 4   
 
 
 
 
 
 
 
 
 
 0 
*Complete fill will be determined by [CONTACT_695401] ( reference  tubes).  
 reference tubes will be provided to illustrate  an acceptable fill 
volume   
 
Testing to be done in Part B include s the following whole blood  parameters and instrument 
platforms  (Table 5).  EDTA s amples from the Test Device  EDTA  and comparator tubes will be 
tested (‘analysis time’) within 4 hours from collection end time. For the contrived samples the full 
panel of analytes may not be run on each pooled set. The specific analytes to be tested for each 
pooled set will be detailed in the Spi[INVESTIGATOR_695355]. Analysis time is defined as the time at which the 
sample is aspi[INVESTIGATOR_695358]  (instrument print out time).  All tubes from the same 
participant  will be processed at the same timeframe  using the same lot of reagents.  Test Device  
EDTA tubes will be  to enable primary tube sampling.  Testing for EDTA 
Tubes will be performed at room temperature . 
 
Table 5: Analytes to be measured in Part  B Natural  and Contrived  Samples  
Analytes  Abbreviation   
 Instrument  
Basophils (%)  BA  
Sysmex XN 1000  
Eosinophils (%)  EO  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943360]  
Hemoglobin  Hgb  
Leukocyte Count  WBC   
Lymphocytes (%)  LY  
Mean Corpuscular 
Hemoglobin  MCH   
Mean Corpuscular 
Hemoglobin 
Concentration  MCHC   
Mean Corpuscular 
Volume  MCV   
Monocytes (%)  MO  
Neutrophils (%)  NE  
Platelet Count  PLT  
Red Cell Distribution 
Width  (RDW -SD / RDW -
CV) RDW -SD / 
RDW -CV  
Instrument flags  N/A  
Hemoglobin A1c  HbA1c   Bio-Rad D -100  
*  
 
 
Relevant instrument flags will be confirmed with manual blood smear s. Blood smears will be 
prepared  on all tubes with instrument flags  (asterisks and IP messages), as appropriate .  For platelet 
flags, 10 high power fields on the smear will be scanned for platelet clumps and rated according 
to the below criteria . 
 
None Seen   
Slight       
 -- 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 46 of 67 
 Moderate   
 
 
Marked   
 
 
7.8 Natural  and Contrived  Sample Acceptance and Rejection Criteria  for Analyte Testing  
Part A:  Samples with the following  visual scores will be rejected:  
- Complete Fill   
- Collection failure  
- Gel Barrier  
- Visual Hemolysis  
 
Part B:  Samples with the following  visual scores will be rejected:  
- Complete Fill   
- Collection failure  
 
7.[ADDRESS_943361] window for each study part (within 4 hours of collection for Part A, and 
within 4 hours of collection for Part B).  
 
If upon the first run, a valid  test result  is not obtained due to  any test run error or no numerical 
value is obtained , a repeat test should be run, volume permitting. Both the original and repeat 
test result will be provided and clearly marked.  
 
For Part B, if a  instrument fla g is noted on the test report, a smear will be prepared 
and reviewed . Check the sample for the following and repeat the test on the  
 
 
1. Adequate sample volume  
2. Mix sample well, (observe for any “hang -up” in sample tube - smaller tubes need more 
time with the inversions to mix well)  
3. Check sample integrity – no clots within sample or on tube top  
 
The first valid result will be used for analysis. If both the first and repeat run is flagged by 
[CONTACT_61140], this  data point should be documented with the asterisk in the study database and 
the first result with the asterisk will be used in the analysis.  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 47 of 67 
  
7.10 Residual Sample Usage  (Natural Sample Group Only)  
 
After study objectives are met,  samples of 
sufficient quantity to collect data supporting the use of the Test Device  for analysis of 
additional analytes.   
 
  
 
 
 
 
 
 
 
 
 
 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  -- Protocol |

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943362] laboratory procedures after the completion of the clinical study 
testing.  
 
7.11 Safety Evaluations  
 
Natural Sample  Group  
Adverse events will be actively collected while the participant is at the site and collected via 
self-report through telephone calls over 7 days  after blood collection.  
 
Contrived Sample  Group  
Safety Evaluation s are outlined in document  
 
8 PARTICIPA NT DISCONTINUATION/WITHDRAWAL  
   
8.1 Discontinuation/Withdrawal  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 49 of 67 
 Natural Sample  Group  
• A participant may withdraw from the study at any time at his/her own request or  may 
be withdrawn at any time at the discretion of the investigator  or sponsor for safety, 
behavioral, compliance, or administrative reasons. This is expected to be uncommon.  
• At the time of disconti nuing from the study , no further  study  assessments will be 
performed . Adverse events that occur and are self -reported by [CONTACT_695402] 
[INVESTIGATOR_695380] 7 days after discontinuation from the study.  
• If the participant withdraws consent for disclosure of future inf ormation, the sponsor 
may retain and continue to use any data collected before such a withdrawal of con sent. 
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site study 
records.  
 
Contrived Sample  Group  
Safety Evaluations are  outlined in document  
 
8.[ADDRESS_943363] to Follow -Up 
 
Not applicable, study will be completed in one visit . 
 
9 ADVERSE EVENTS AND DEV ICE DEFICIENCIES  
 
9.1 Definitions of Events  
 
9.1.1 Adverse E vents (AEs)  
 
An adverse event is defined as any untoward medical occurrence, 
inappropriate patient management decision, unintended disease or injury, or 
untoward clinical signs in participants, users, or other persons, with any 
connection to study related activities, whether or not related to the IVD 
medical device under investigat ion (ISO [ZIP_CODE]).   In this study, participant 
AEs are limited to those occurring immediately before, during, and 
immediately after specimen collection.   Also, based on the nature of the study, 
test results will not be used for patient management decisions.  
 
For the purpose of this study, Adverse events will be collected by [CONTACT_695403] (once discharged). If 
an adverse event occurs during this time the PI [INVESTIGATOR_695381] -up with 
the participant.   The cli nical course of the event will be followed according to 
accepted standards of medical practice until the event resolves, stabilizes, or 
in the opi[INVESTIGATOR_689], is no longer considered clinically 
significant.   The Investigator must document the adverse event outcome on 
the AE CRF through a follow -up call to the participant.  
                 -- Protocol | 
Downloaded on [ADDRESS_943364] 2023
System Version Number 1.0

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943365] 
discontinuation by [CONTACT_695404].  
 
 
 
9.1.2 Serious Adverse Events (SAEs)  
 
A serious adverse event is defined by [CONTACT_5891] [ZIP_CODE] and/or 21 CFR 803.3 as an adverse 
event that:  
a. led to death  
b. led to serious deterioration in health that resulted in life -threatening illness 
or injury, resulted in permanent impairment  
c. life threatening (refe rs to any event in which the subject was at risk of 
death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe)  
d. required intervention to prevent permanent impairment/damage  
e. required in patient hospi[INVESTIGATOR_059]/prolonged hospi[INVESTIGATOR_059], or resulted in 
medical/surgical intervention to prevent life -threatening illness/injury or 
permanent impairment; or  
f. led to fetal distress, fetal death, or a congenital abnormality or birth defect  
g. importan t medical event that may require intervention to prevent one of the 
preceding conditions  
 
9.1.[ADDRESS_943366] (ADE)  / Serious Adverse Device Effect (SADE)  
 
An adverse device effect is defined as any adverse event that is considered to be 
related to the use of an investigational medical device. This definition includes any 
event resulting from insufficiencies or inadequacies in the instructions for use, 
deployment, implantation, or operation or any malfunction of the investigational 
device (study device) and includes any event that is a result of a user error.  
 
A serious adverse device effect (SADE) is defined as an ADE  that has resulted in 
any of the consequences characteristic of an SAE.  
 
9.1.4 Unanticipated (Serious) Adverse Device Effect (UADE/[LOCATION_003]DE)  
 
An unanticipated ( serious) adverse device effect (UADE/[LOCATION_003]DE) is any (serious)  
adverse device effect on health or safety or any life -threatening problem or death  
caused by, or associated with, a study device, which by [CONTACT_5942], incidence,  
severity, or outcom e has not been identified in the current instruction s for use 
and/or current version of the risk  analysis report, or any other unanticipated serious 
problem associated with a device  that relates to the rights, safety,  or welfare of 
participant s. 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 51 of 67 
 UADEs/[LOCATION_003] DEs will be reported to FDA as required by 21 CFR Part 812.  
 
9.2 Severity of Adverse Events  
 
Each AE sh all be assessed for its severity, or the intensity of an event, experienced by  [CONTACT_695405].  
 
Severity Rating  Description  
Mild  Event, s igns, or symptoms that do not interfere with the participant ’s 
daily activity, are usually considered self -limiting, can be treated with 
non-prescription type medications , and do not require medical 
intervention  
Moderate  Event may interfere or cause low level inconvenience with the 
participant ’s daily activity. Requires medical intervention and/or 
treatment ; however, unlikely to require hospi[INVESTIGATOR_690344] -threatening in nature  
Severe  Event may cause significant  discomfort to the participant  and/or 
interferes with the participant ’s daily activity. Requires medical 
intervention and/or treatment to preclude a permanent impairment ; 
may be life threatening and /or require hospi[INVESTIGATOR_059]  
 
9.3 Relationship of Adverse Even t to Device(s)/Procedure  
 
Each AE will be assessed for its relationship to the study device or procedure  according to 
the following guidelines.  
 
A.  Assess each AE for its relationship to the device or procedure.  
 
• Device  Related : This category should be restricted to AEs directly 
attributable to any study device used during blood collection . 
 
• Procedure:  A procedure includes any study -related activity performed 
during the participant’s study visit . 
 
B.  The following categories shall be used for assigning the certainty of the 
relatedness.  
 
Relatedness  Description  
Not Related  Event is independent of study intervention and/or evidence 
exists that the event is related to another etiology. There must 
be an alternative etiology documented by [CONTACT_15370].  
Unlikely Related  Event in which the temporal relationship to study  intervention 
makes a causal relationship improbable (e.g., the event did not 
occur within a reasonable time of the study device use) and i n 
which underlying disease provides plausible explanations (e.g., -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 52 of 67 
 the participant’s clinical condition other concomitant 
treatments).  
Likely Related  Event in which t here is evidence to suggest a causal relationship 
and the influence of other factors is le ss likely. The event occurs 
within a reasonable time after use of the study device and is less 
likely to be attributed to concurrent disease.  
Related  Event in which there is clear evidence to suggest a causal 
relationship and other possible contributing f actors can be ruled 
out. The event occurs in a plausible time relationship to use of 
the study device and cannot be explained by [CONTACT_388669].  
 
 
9.4 Reporting of Events  
 
For all adverse events, all sections of the appropriate Case Report Form (CRF) must  be 
completed.  
 
• All SAEs, SADEs, and/or UADEs/[LOCATION_003]DEs  must be reported to the Sponsor within 
one (1) working day of the site/investigator becoming aware of the event.    
 
• De-identified copi[INVESTIGATOR_690345] 72 hours of knowledge, as appropriate.  
 
It is the responsibility of the Investigator to r eport adverse events to individual Institutional 
Review Boards (IRBs)/Ethics Committees (ECs) and/or regulatory authorities  according 
to the local regulations in each participating country.  
 
9.[ADDRESS_943367].   Device deficiencies also include use errors and inadequate labeling.   
This applies to: devices used to treat t he participant , or devices in which the package was 
opened, but the device was not used for treatment, or devices with which treatment was 
attempted, but the device did not remain through the entire study procedure/ period.  
 
 
 
 
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 53 of 67 
  
•  
  
  
  
  
   
 
If the device deficiency was associated with an AE, the reporting provisions for AEs,  
ADEs, SAEs, SADEs and UADEs/[LOCATION_003]DEs  apply.  
 
Reported deficiencies will be investigated and reported under [ADDRESS_943368] a thorough investigati on. 
 
It is the responsibility of the Investigator to notify the IRB/EC of such device deficiencies  
in accordance with the IRB/EC and/or the Competent Authority’s local regulations.  
 
10 STATISTICAL METHODS  
 
The statistical analysis plan (SAP)  will be finalized prior to database lock  and will include a 
more technical and detailed description of the statistical analyses described in the following 
sections . This section includes a summary of the planned statistical analyses of the most 
important endpoints including primary and key secondary endpoints.  
 
10.[ADDRESS_943369] 90% power to ensure that mean 
biases and confidence intervals are within the clinically acceptable limits (CAL) at medical  
decision  points, assuming no true bias between the tubes, residual SD, or CV ≤ CAL, and 
collected dat a extend past the medically relevant points . 
 
10.3 Analysis Population  
 
Safety analysis (summary of all device/procedure - related AEs) will be conducted on all 
enrolled participants . 
 -- Protocol |

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 54 of 67 
 All data collected will be reviewed for possible exclusion based on signific ant protocol 
deviations.  Analysis will be performed on the resulting Per -Protocol (PP) dataset. Missing 
values will not be imputed and will not be included in any analyses.  
 
Visual assessments : all collected tubes will be included in the summaries  and ana lyses .  For 
duration of sample collection, only tubes with complete fill will be included  in the 
summaries  and analyses . 
 
Analytes:  Pre -specified specimen exclusion criteria will be applied . Analysis will be 
performed on all first reported valid result unless a reason is provided for specific 
exclusions. Reasons for such exclusions will be included in the statistical report. If repeat 
tests are performed, a list of participants and tubes showi ng the initial and repeat results 
will be provided, showing which result is used in the analyses.  For each investigational 
device vs. respective comparator device comparison, only participants with valid results in 
both tubes will be included in the bias a nalysis.    
 
In addition, for study Part B, platelet analysis, a primary analysis of platelet results will be 
conducted excluding samples (from all tube types) with platelet flags confirmed with 
platelet clumps on smear review. Platelet flags and smear review data will be tabulated per 
tube type  and sample type . An additional analysis will be done including all data, with and 
without platelet flags.   
 
 
 
10.4 General Considerations  
 
An alpha level of 5% will be  used for all analyses. For equivalence testing with analytes 
having a CAL,  this corresponded to obtaining 90% con fidence intervals (associated with 
95% two 1 -sided tests).  
 
For all analytes and continuous response metrics  summary statistics including sample size, 
mean, standard deviation ( excluding  analytes), range of data obtain ed (minimum and 
maximum value) will be provided for each device.  
 
For visual  observation s and categorical observations, number of observations and percent 
in each category will be summarized for each device.  
 
  
 
  
   
  
  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 55 of 67 
  
 
   
  
  
  
  
  
  
  
 
10.5 Analysis Methods  
 
10.5.1  Clinical Equivalence  Endpoints  
For each analyte and each comparison, Deming regression (weighted Deming for analytes 
with percent CAL) or Passing -Bablok Regression will be use d to estimate average 
differences between the investigational device and comparator device at medical decision  
levels (MDLs) for each analyte .  Average differences with 95% confidence limits will be 
compared to the CALs to determine clinical equivalence between the devices.  
 
10.5.2   Visual Observations and Supplemental Measurements  Endpoints  
 
The distribution of visual observation ratings for each tube type will be  tabulated  and 
summarized . No analysis will be performed on the visual  observation s data from this  
protocol alone; visual observations  for Natural Samples  from multiple protocols will be  
combined for analysis, as specified in a separate Meta -Analysis plan. For the Test Device  
 a meta -analysis plan will assess  for the Natural Samples the  plasma free hemoglobin,  
serum volume,  duration of sample collection, fibrin mass, complete barrier formation, and 
complete fill. For the Test Device  EDTA , a meta -analysis plan will assess  for the Natural 
Samples the  whole blood volume , complete fill , duration of sample collection, and 
instrument flag frequencies.  
 
10.5.3   Safety Analysis  Endpoints  
A summary of all Device/procedure - related adverse events (AEs)  will be provided . 
 
10.6 Interim Analysis  
 
 
 
 
 
 
    -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943370] MAINTENANCE  
 
11.1 Case Report Forms  
 
The Investigator is responsible for ensuring the completeness and accuracy of all study  
documentation.  
 
All required clinical data will be collected/documented in sponsor -provided paper source 
and electronic Case Report Forms (CRFs). FDA 21 CFR 11 is follo wed as well as other 
applicable legislation on the handling of  electronic data. Modification of the CRF s will 
only be  made if deemed necessary by [CONTACT_1052]/or the appropriate regulatory body.  
 
Site numbers and  participant  numbers will be used to trac k participant  information 
throughout the study.   Participant  personal information will be pseudonymized /de-
identified . 
 
11.[ADDRESS_943371] 
of data, such as for subjective  data (e.g., pain scales, questionnaires) , these data may be 
recorde d directly on the CRF (s) and the CRF is then considered to be the source.   
 
11.3 Data Management  
 
Data management is th e responsibility of the Sponsor.   Data from completed CRFs will be 
managed in a secured, controlled database .   A Data Management Plan (DMP)  will be 
developed that outlines the procedures used for data review, database cleaning and 
issuing/resolving data queries. Procedures for validations and data storage will also be 
contained within the DMP.  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943372] Retention  
 
The Investigator shall retain a ll study records for a minimum of two (2) years after the  later 
of the following two dates: the date on which the study is terminated/completed or  the date 
that the records are no longer required for purposes of supporting a pre -market  approval 
application  or a notice of completion of a product development protocol  (21 CFR Part 
812.140 ). The  data for some of these records may be available in computerized form but 
the final  responsibility for maintaining study records remains with the Investigator.  
 
The Inve stigator may withdraw from the responsibility to maintain records for the period  
required by [CONTACT_690372]. Notice of a transfer shall be given to the Sponsor and  
FDA, if applicable,  not later than ten (10) working days after the transfer occurs . 
 
[ADDRESS_943373] 
obtained written IRB/EC app roval (as required) for participation in this study, who have 
completed all required study documentation, and who have been qualified by [CONTACT_1034].  
Investigators must maintain control over all study products, and ensure they are used in 
accordance with this protocol.  Failure to do so may result in the Sponsor suspending or 
terminating the study at the Investigator’s site.  
  
The Investigator will ensure that study products are only dispensed to participant s (or used 
for specimens) properly enrolled in t he study. The Investigator must maintain records of 
receipt, disposition, return and/or destruction of all study products. All investigational 
study products released to the site must be accounted for at the unit level prior to study 
close out, regardless of disposition.  The S ponsor -Monitor will regularly review all records 
regarding study product accountability.  
 
The Sponsor will maintain records that document the shipment, receipt, disposition, return 
and/or destruction of study products.  
 
12.[ADDRESS_943374] operating procedures and the study -
specific Monitoring Plan.   
 
Prior to study start, a study initiation visit  (SIV)  will be conducted to review with the 
Investigator(s) and staff the provisions and proper  conduct of this study. This visit will 
include a detailed review of this protocol,  verification that all necessary documents are on 
file at the investigational site and  confirmation of IRB/EC approvals.   -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 58 of 67 
  
During the study, routine monitoring visits  (RM Vs) will be conducted to assure the site 
continues to adhere to the protocol, the investigator agreement, and regulations regarding 
conduct of clinical studies.  The Sponsor -Monitor will confirm that the ICF to be used is 
the version  approved by [CONTACT_1201]/EC, confirm the applicable national privacy laws have 
been  followed , verify that  all necessary documents are on file at the investigational site and 
confirm that the re are  provisions to continue and maintain all documents and records 
throughout the study as  required by [CONTACT_5279]. These monitoring visit s will 
assess continued protocol  compliance, adequate participant  enrollment, accurate data  
reporting,  monitoring of participant  safety through identification and/or review of any 
device -related  AEs, UADEs, or SAEs, device accountability, continued maintenance,  and 
calibration of  study -specific equipment (if applicable), and continued IRB/EC acceptance 
of the  study.  
 
At the completion of the study, the Sponsor -Monitor  will conduct a final close -out visi t or 
COV . The  purpose of this visit may include but is not limited to collecting all outstanding 
study data  documents, confirming that the Investigator’s files are accurate and complete, 
reviewing  the record retention requirements with the Investigator, providing for the return 
of unused  devices to the Sponsor, reviewing records which account for device shipments 
and ensuring that all applicable requirements for closure of the study are met.  
 
12.[ADDRESS_943375] agree to the inspection of all study related records and give 
the auditor/inspector direct access to source documents for verification of data on CRFs.  
The participant ’s anonymity must be ensured,  and data checked during the audit must  
remain confidential.  
 
As soon as the Investigator is aware of an upcoming inspection/audit by [CONTACT_36296], he/she will promptly inform the Sponsor .  As agreed with the Investigator, 
Sponsor  personnel may be present at the site during the inspec tion. 
 
12.[ADDRESS_943376] the life or physical well -being of a participant , protoc ol 
deviations are not permitted.  The S ponsor and the investigational site’s IRB/EC must be 
notified immediately if an emergency situation arises in which the safety of a participant  
may require immediate intervention different than that defined in the pro tocol.  This must 
be followed by [CONTACT_695406], -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 59 of 67 
 within five (5) working days from the date of the emergency action  in accordance with the 
governing IRB/EC’s requirement.   
 
It is the Investigator’s responsibility to ensure that there are no deviations from the  
Protocol.  Except in an emer gency , when a protocol deviation is planned or anticipated, the 
Sponsor should be contact[CONTACT_291444].  Any and all deviations must be recorded on the 
appropriate  CRF regardless of whether medically justifiable  or sponsor approved .  Upon 
evaluation by [CONTACT_1034], actions may be required to prevent additional deviations, such 
as retraining of the site, implementation of additional site procedures, and more frequent  
monitoring.  If these steps fail, more serious measures, up to and including termination of 
enrollment at the site.  
 
12.4.[ADDRESS_943377] (OSI) is defined as an event that is outside of the 
reasonable control of the study site or Principal Investigator.  The event prevents 
completion of specimen processing and/or testing or could impact the integrity of 
the evaluation of data.  Examples of OSI include but are not limited to specimen 
handling accidents, specimen  shippi[INVESTIGATOR_007]/transport mishaps, and instrument/  ancillary 
device malfunction (excluding study device).   
 
An occurrence of special interest must be recorded on the appropriate CRF.  Upon 
evaluation by [CONTACT_1034], actions may be required to prevent additional  
occurrences, such as retraining of the site, implementation of additional site 
procedures, and/or more frequent monitoring.   
 
[ADDRESS_943378]  
appropriate research experience and infrastructure to ensure adher ence to this protocol  
and enrollment of sufficient numbers of evaluable participant s. The curriculum vitae of  the 
Investigator(s), Sub -Investigator(s) and Study Coordinator(s) will be maintained in  the 
Sponsor’s files as documentation of qualification by [CONTACT_3903].  
 
The Principal Investigator [INVESTIGATOR_695382] e Investigator Agree ment pages of this protocol, 
agreeing to  comply with all applicable regulations and the requirements of this study as  
per the clinical study agreement .  
 
Any site that is deactivated prior to initial enrollment, either by [CONTACT_695407], may be replaced.  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943379] training  will be  
provided by [CONTACT_690377]. Additional study 
staff (e.g., Sub-Investigator(s) ) will also require device training provide d from the Sponsor 
or proctoring  by [CONTACT_978]. All training will be documented and filed at the investigational site 
and with  the Sponsor.  
 
13.3 Required Documents  
 
An Investigator may not screen or enroll participant s until authorized to do so by [CONTACT_55688]. At a minimum, the following documentation should be received by [CONTACT_695408]:  
• Fully executed Non-disclosure Agreement (NDA) between PI /site and Sponsor ; 
• CVs., signed and dated within 2 years of study start  for the PI [INVESTIGATOR_34511] -
Investigator(s);  
• CVs. for Study Coordinator(s);  
• Signed CSA by [CONTACT_976] /site (or designee);  
• Signed Investigator Agreement Page  by [CONTACT_976] [INVESTIGATOR_34511] -Investigator(s);  
• Signed Financial Disclosure Statement by [CONTACT_976] [INVESTIGATOR_34511] -Investigator(s);  
• Completed and Signed Training Log  by [CONTACT_976] [INVESTIGATOR_34511] -Investigator(s);  
• Study Personnel Identification list;  
• Written approval from the IRB/EC of both the protocol and ICF, and any other  
• applicable protocol specific material; and  
• IRB/EC Membership List, Assurance of Compliance Fo rm, or equivalent.  
 
13.4 Publication Policy  
 
The sponsor believes that results of applicable clinical studies  should be published in peer -
reviewed literature in a timely, accurate, complete,  and balanced manner, regardless of 
study outcomes , whenever possible .  As such, at the conclusion of this study, an article 
may be prepared for publication in a reputable  scientific journal.   Formal presentation (s) 
or publication (s) of data collected from this study will be considered as a joint publication 
by [CONTACT_093](s) and the appropriate personnel of the Sponsor . Authorship will be 
based on generally accepted criteria of the ICMJE (International Committee of Medical 
Journ al Editors) and  determined by [CONTACT_11402].  
 
The publication of the principal results from any single -center experience within the study 
is not allowed until the preparation and publication of the multicenter results. Exceptions 
to this rule require th e prior approval of the Sponsor. The analysis of other pre -specified 
and non -pre-specified endpoints will be performed by [CONTACT_4885]. Such 
analyses, as well as other proposed investigations or manuscripts will require the approval 
of the S ponsor.  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  [ADDRESS_943380] of 
2007 (FDAAA), the Sponsor will register this study and disclose study results in a publicly 
accessible database (i.e., ClinicalTrials.gov).  Thi s study will be registered no later than 21 
days after commencing enrollment.  Study results will be posted to the website within 12 
months after regulatory and health authority approval.  
 
13.6 Termination of Study  
 
The Sponsor reserves the right to suspend enr ollment or terminate the study at any time  for 
any reason.  Th e Sponsor may suspend enrollment or terminate the study at a  specific 
investigational site for reasons including, but not limited to, inadequate data  collection, low 
participant  enrollment rate,  achievement of the total enrollment, conditions  imposed by [CONTACT_54455]/EC and/or non -compliance with this protocol or other  clinical research 
requirements. Written notice will be submitted to the Investigator in  advance of such 
termination.  
 
In the  event of study suspension or termination, the Sponsor will send a report outlining  
the circumstances to the IRB/EC, and all Investigators and Regulatory Authorities as  
required by [CONTACT_5151].  
 
14 ETHICAL AND REGULATORY CONSIDERATIONS  
 
14.1 IRB/EC Approval  
 
Investigators or designees must submit the study protocol, Informed Consent Form (if 
applicable) , and all other  locally  required documentation to an appropriate  IRB/EC and 
obtain study -specific written approval  (favorable opi[INVESTIGATOR_1649])  before being allowed to 
participate in the study. Before commencement of the  study, the Investigator or designee 
must provide the Sponsor with written documentation  of such approval.  The IRB/EC must 
give written renewal of the original approval at  least annually to continue the s tudy. A copy 
of the written renewal must be provided to  the Sponsor.  
 
The IRB/EC will be notified of any amendments to the protocol, as well as possible 
associated information and consent form changes, where applicable, and written approval 
(favorable opin ion) will be obtained prior to implementation, as applicable.  
 
The Investigator or designee is responsible for fulfilling any conditions of approval imposed 
by [CONTACT_1201]/EC, such as regular safety reporting, study  timing, etc. The Investigator or 
designee wi ll provide the Sponsor with copi[INVESTIGATOR_695383].  
 
14.2 Informed Consent and Confidentiality  (Natural Samples)  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 62 of 67 
 Prior to any study procedure, the Investigator (or designee) must explain to each participant  
in layman’s terms, the nature of the study, its purpose, expected duration, and the risks  and 
benefits of study participation. Also, participant  will be informed of uses and  disclosures 
of their medical information for research purposes, and their rights to access  information 
about them. All applicable national privacy laws (e.g., HIPAA requirements  in the US) will 
be followed in this study. The partic ipants  must be informed of their right to  withdraw from 
the study at any time and for any reason without sanction, penalty, or loss  of benefits to 
which th ey are otherwise entitled, and that  withdrawal from the study will  not jeopardize 
their future medical care. Participants  will be informed of their right to new  information 
and/or findings relating to the clinical study, and the process by [CONTACT_695409]. After this explanation, given sufficient time to decide  whether to 
participate, before any study procedure is conducted, and before entering the  study, the 
participant  must voluntarily provide consent in accordance with 21 CFR Par ts 50  and 56 
and ISO [ZIP_CODE]:2011(E). The participant  will receive a copy of his/her signed ICF.  
 
14.2.[ADDRESS_943381] by [CONTACT_737], study  
staff, and the Sponsor.  Participant confidentiality and anonymity will be 
maintained by [CONTACT_690381], documentation, or clinical 
samples submitted to the Sponsor . 
 
Any data collected meeting the definition of protected/confidential health 
information or personal identifying information w ill be collected and maintained 
using the designated authorizations and following privacy procedures as specified 
in the applicable health authority regulations.   
 
The Sponsor -Monitor, authorized repr esentatives of the sponsor, and/or applicable 
Health Au thorities may inspect all documents and records required to be maintained 
by [CONTACT_737].  The Investigator/ Site will permit access to such records.  
 
14.3 Regulatory Status  
 
The Sponsor has determined and documented this to be a n IDE Exempt study based on  
congruency with 21 CFR 812.3.  This determination is based on the following assessment 
of the investigational device:  
 
• Is not intended as an implant;  
• Is not purported or represented to be for a use in supporting or sustaining human 
life; 
• Is not intended for a use of substantial importance in diagnosing, curing, mitigating, 
or treating disease, or otherwise preventing impairment of human health; and,  
• Does not present a potential for serious risk to the health, safety, or welfare of a 
participant.  
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 63 of 67 
 Classifi cation of non-significant risk  is documented in the Study Risk Assessment Form . 
 
14.4 Statement of Compliance  
 
This clinical investigation will be conducted in compliance with the protocol and  following 
regulatory requirements:  
• 21 CFR 50, 54, 56 and 812;  
• 21 CFR  812.28(a)(1) (Good Clinical Practice) ; 
• Ethical principles of the Declaration of Helsinki , in its current revision;  and 
• Applicable sections of the national laws and regulations.  
 
The clinical investigation will not commence at a clinical site until approva l (favorable 
opi[INVESTIGATOR_1649] ) from the respective IRB/EC has been received. All additional requirements 
imposed by  [CONTACT_1201]/EC(s) will be followed. Involvement of the national competent 
authorities  (e.g., by [INVESTIGATOR_520383], seeking authorization ) will be accomplished  as required 
by [CONTACT_695410].  
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 64 of 67 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 65 of 67 
 16 APPENDICES  
 
Appendix A: Reference Ranges, Critical Values, and Assay Measurable Ranges per Parameter  
Appendix B: Overview of Spi[INVESTIGATOR_695384]  
 
 
 
 
 
 
 
 -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 66 of 67 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  -- Protocol | 

Protocol Number:   CONFIDENTIAL  
Version: 4.0 
Date:  07 September  2022  
 
Page 67 of 67 
  
Appendix B: Overview of Spi[INVESTIGATOR_695385]:  Full details of the contriving approach  and preparation steps to create abnormal low 
and abnormal high samples  will be defined under a separate Spi[INVESTIGATOR_695355]. However, contrived 
samples will be created  using the general approach below, using  
 and then prepared by [CONTACT_695411][INVESTIGATOR_28884]/dilution material. Once contrived 
samples are prepared, they will be transferred into the Test Device  and comparator  tubes for 
processing. Multiple sets of contrived samples can be prepared from the  blood collected from one 
participant. Collection metrics such as duration of collection, whole blood volume,  and serum 
volumes will not be collected for contrived samples. All visual observations will be collected 
except for  “collection failure ” as these samples are indirectly collected. Following visual 
observations, all samples are expected to be processed and tested as per  
handling, processing, and testing .  
 
-- Protocol | 

-- 
